Clinical Trial Update: Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis [Phase 2]

View source ↗

Summary

Phase II safety and acceptability study of an injectable pre-exposure prophylaxis product (TMC278LA) completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TMC278LA (rilpivirine long-acting formulation)

Snippet

Sponsor: PATH | Conditions: Human Immunodeficiency Virus (HIV) | Phase 2 | Status: COMPLETED | Results posted: 2018-07-26